Tag Archives: Intellia

Intellia Therapeutics (NTLA) stock plummeted on Monday after the biotechnology company announced an update from its MAGNITUDE and MAGNITUDE-2 Phase 3 clinical trials. These clinical trials tested the use of the company’s nex-z gene-editing technology as a treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN). ATTR-CM is an often fatal condition in which abnormal transthyretin protein fibrils build …

Intellia Therapeutics said Monday it is pausing two late-stage CRISPR gene-editing trials after a patient in one study was hospitalized with liver damage.  The company’s stock plummeted more than 35% in morning trading.  Liver damage has been a known risk for many CRISPR-based medicines in development, in part because they often involve trying to knock out or modify a gene …

Intellia Therapeutics Stock Drops as Safety Fears Emerge in Drug Trial  Barron’s For Intellia Therapeutics, CRISPR drug’s safety concern is an existential threat  statnews.com Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)  Intellia Therapeutics Intellia Pauses Crispr Trials After Patient Is Hospitalized  Bloomberg.com Intellia pauses phase 3 CRISPR trials after patient is hospitalized  Fierce Biotech Source link

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)  Intellia Therapeutics Intellia pauses two late-stage CRISPR gene-editing trials after emergence of safety concern  statnews.com Intellia pauses trials after serious liver event in gene therapy patient  Investing.com Nigeria Intellia Temporarily Pauses Dosing For MAGNITUDE And MAGNITUDE-2 Phase 3 Clinical Trials Of Nex-z  Nasdaq Intellia pauses late-stage trials of gene-editing treatment after serious …